JP2015500307A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015500307A5 JP2015500307A5 JP2014546445A JP2014546445A JP2015500307A5 JP 2015500307 A5 JP2015500307 A5 JP 2015500307A5 JP 2014546445 A JP2014546445 A JP 2014546445A JP 2014546445 A JP2014546445 A JP 2014546445A JP 2015500307 A5 JP2015500307 A5 JP 2015500307A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- formula
- hydroxy
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *N(*)Cc1c(CO*)c(Br)c2[n]1ncnc2N Chemical compound *N(*)Cc1c(CO*)c(Br)c2[n]1ncnc2N 0.000 description 5
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11193841 | 2011-12-15 | ||
| EP11193841.1 | 2011-12-15 | ||
| PCT/EP2012/074977 WO2013087578A1 (en) | 2011-12-15 | 2012-12-10 | Disubstituted benzothienyl-pyrrolotriazines and their use as fgfr kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015500307A JP2015500307A (ja) | 2015-01-05 |
| JP2015500307A5 true JP2015500307A5 (cg-RX-API-DMAC7.html) | 2015-07-23 |
| JP6050829B2 JP6050829B2 (ja) | 2016-12-21 |
Family
ID=47326168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014546445A Expired - Fee Related JP6050829B2 (ja) | 2011-12-15 | 2012-12-10 | 二置換ベンゾチエニル−ピロロトリアジンおよびｆｇｆｒ阻害剤としてのその使用 |
Country Status (42)
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10388493B2 (en) | 2011-09-16 | 2019-08-20 | Lam Research Corporation | Component of a substrate support assembly producing localized magnetic fields |
| UY34484A (es) * | 2011-12-15 | 2013-07-31 | Bayer Ip Gmbh | Benzotienilo-pirrolotriazinas disustituidas y sus usos |
| TW201536293A (zh) | 2013-07-18 | 2015-10-01 | Taiho Pharmaceutical Co Ltd | 對ｆｇｆｒ抑制劑具耐受性之癌的治療藥 |
| JP6084291B2 (ja) | 2013-07-18 | 2017-02-22 | 大鵬薬品工業株式会社 | Ｆｇｆｒ阻害剤の間歇投与用抗腫瘍剤 |
| WO2015061369A1 (en) * | 2013-10-21 | 2015-04-30 | Genosco | Substituted pyrimidine compounds and their use as syk inhibitors |
| US20180333418A1 (en) * | 2014-12-11 | 2018-11-22 | Bayer Pharma Aktiengesellschaft | Use of pan fgfr inhibitors and method of identifying patients with cancer eligible for treatment with a pan fgfr inhibitor |
| KR20180013851A (ko) * | 2015-03-09 | 2018-02-07 | 바이엘 파마 악티엔게젤샤프트 | 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린-함유 조합물 |
| BR112018012914B1 (pt) | 2015-12-22 | 2023-04-18 | SHY Therapeutics LLC | Composto, uso de um composto e composição farmacêutica |
| EP3424505A4 (en) | 2016-03-04 | 2019-10-16 | Taiho Pharmaceutical Co., Ltd. | PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| KR102558066B1 (ko) | 2016-03-28 | 2023-07-25 | 인사이트 코포레이션 | Tam 억제제로서 피롤로트리아진 화합물 |
| CN107513068A (zh) * | 2016-06-16 | 2017-12-26 | 中国科学院上海药物研究所 | 一种具有fgfr抑制活性的新型化合物及其制备和应用 |
| CN110300589B (zh) | 2016-12-16 | 2023-03-10 | 囊性纤维化基金会 | 作为cftr增效剂的双环异杂芳基衍生物 |
| AU2018288841B2 (en) | 2017-06-21 | 2022-09-29 | SHY Therapeutics LLC | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease |
| RU2771311C2 (ru) * | 2017-08-15 | 2022-04-29 | Сиэсписи Чжунци Фармасьютикал Текнолоджи (Шишцзяжуан) Ко., Лтд. | Ингибитор fgfr и его медицинское применение |
| WO2019034075A1 (zh) * | 2017-08-15 | 2019-02-21 | 南京明德新药研发股份有限公司 | Fgfr和egfr抑制剂 |
| IL273579B2 (en) | 2017-09-27 | 2025-10-01 | Incyte Corp | Salts of pyrrolizidine derivatives used as Tm inhibitors. |
| WO2019081346A1 (en) * | 2017-10-25 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | PROCESS FOR THE PREPARATION OF BENZOTHIOPHEN-2YL BORONATE |
| WO2019105734A1 (en) | 2017-11-28 | 2019-06-06 | Bayer Consumer Care Ag | Combinations of copanlisib |
| TWI790364B (zh) | 2018-03-19 | 2023-01-21 | 日商大鵬藥品工業股份有限公司 | 包含烷基硫酸鈉之醫藥組合物 |
| WO2019180141A1 (en) | 2018-03-23 | 2019-09-26 | Bayer Aktiengesellschaft | Combinations of rogaratinib |
| HRP20250676T1 (hr) | 2018-06-29 | 2025-08-01 | Incyte Corporation | Formulacije inhibitora axl/mer |
| WO2020132071A1 (en) | 2018-12-19 | 2020-06-25 | Shy Therapeutics. Llc | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and f1brotic disease |
| US20220098201A1 (en) * | 2019-01-31 | 2022-03-31 | Bayer Aktiengesellschaft | The monohydrate of rogaratinib hydrochloride and solid states thereof |
| CA3130247C (en) * | 2019-02-15 | 2024-02-13 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd | Fgfr inhibitor compound in solid form and preparation method therefor |
| WO2020170355A1 (ja) * | 2019-02-20 | 2020-08-27 | 大鵬薬品工業株式会社 | Ｆｇｆｒ１変異腫瘍の治療方法 |
| CN109928976A (zh) * | 2019-02-26 | 2019-06-25 | 泰州亿腾景昂药业有限公司 | 一种工业化生产eoc317的方法 |
| CN119874707A (zh) * | 2019-05-13 | 2025-04-25 | 传达治疗有限公司 | Fgfr抑制剂和其使用方法 |
| WO2021089005A1 (zh) * | 2019-11-08 | 2021-05-14 | 石药集团中奇制药技术（石家庄）有限公司 | 一种fgfr抑制剂的用途 |
| CN111004234A (zh) * | 2019-11-28 | 2020-04-14 | 湖南农业大学 | 一种2-苯基咪唑并[1,2-α]吡啶类化合物的C3位卤化方法 |
| CN115697343A (zh) | 2020-03-06 | 2023-02-03 | 因赛特公司 | 包含axl/mer和pd-1/pd-l1抑制剂的组合疗法 |
| CN117402161A (zh) * | 2022-07-06 | 2024-01-16 | 上海科恩泰生物医药科技有限公司 | 一种具有fgfr抑制作用的亚砜亚胺类化合物、包含其的药物组合物及其用途 |
| KR20250164828A (ko) | 2023-03-30 | 2025-11-25 | 레볼루션 메디슨즈, 인크. | Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL204437B1 (pl) | 1999-05-21 | 2010-01-29 | Bristol Myers Squibb Co | Pochodna pirolotriazyny i jej zastosowanie oraz kompozycja farmaceutyczna i jej zastosowanie |
| WO2001019828A2 (en) | 1999-09-17 | 2001-03-22 | Basf Aktiengesellschaft | Kinase inhibitors as therapeutic agents |
| JPWO2004096806A1 (ja) * | 2003-04-30 | 2006-07-13 | 大日本住友製薬株式会社 | 縮合イミダゾール誘導体 |
| DE10327439A1 (de) * | 2003-06-18 | 2005-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| MXPA06011423A (es) | 2004-04-02 | 2007-01-23 | Osi Pharm Inc | Inhibidores de proteina cinasa heterobiciclica sustituida en el anillo 6,6-biciclico. |
| UY28931A1 (es) | 2004-06-03 | 2005-12-30 | Bayer Pharmaceuticals Corp | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis |
| TW200635927A (en) * | 2004-12-22 | 2006-10-16 | Bristol Myers Squibb Co | Synthetic process |
| WO2007056170A2 (en) | 2005-11-02 | 2007-05-18 | Bayer Healthcare Ag | Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
| US7700594B2 (en) * | 2005-11-17 | 2010-04-20 | Osi Pharmaceuticals, Inc. | Fused bicyclic mTOR inhibitors |
| US7514435B2 (en) | 2005-11-18 | 2009-04-07 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| EP1957485B1 (en) | 2005-12-02 | 2013-02-13 | Bayer HealthCare, LLC | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| CA2631732C (en) | 2005-12-02 | 2012-12-18 | Bayer Healthcare Llc | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase |
| PE20070855A1 (es) * | 2005-12-02 | 2007-10-14 | Bayer Pharmaceuticals Corp | Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas |
| CN101389630A (zh) * | 2005-12-29 | 2009-03-18 | 艾博特公司 | 蛋白激酶抑制剂 |
| US8124759B2 (en) | 2007-05-09 | 2012-02-28 | Abbott Laboratories | Inhibitors of protein kinases |
| US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
| WO2010126960A1 (en) | 2009-04-29 | 2010-11-04 | Locus Pharmaceuticals, Inc. | Pyrrolotriazine compounds |
| UY34484A (es) * | 2011-12-15 | 2013-07-31 | Bayer Ip Gmbh | Benzotienilo-pirrolotriazinas disustituidas y sus usos |
-
2012
- 2012-12-03 UY UY0001034484A patent/UY34484A/es unknown
- 2012-12-10 HU HUE12798738A patent/HUE029582T2/en unknown
- 2012-12-10 EA EA201400707A patent/EA029556B1/ru not_active IP Right Cessation
- 2012-12-10 LT LTEP12798738.6T patent/LT2791140T/lt unknown
- 2012-12-10 KR KR1020147019406A patent/KR102057444B1/ko not_active Expired - Fee Related
- 2012-12-10 PT PT127987386T patent/PT2791140T/pt unknown
- 2012-12-10 PE PE2014000926A patent/PE20141855A1/es active IP Right Grant
- 2012-12-10 PL PL12798738T patent/PL2791140T3/pl unknown
- 2012-12-10 SG SG11201402325QA patent/SG11201402325QA/en unknown
- 2012-12-10 ES ES12798738.6T patent/ES2591203T3/es active Active
- 2012-12-10 MX MX2014006905A patent/MX367158B/es active IP Right Grant
- 2012-12-10 CN CN201280069882.6A patent/CN104245700B/zh not_active Expired - Fee Related
- 2012-12-10 BR BR112014014531-8A patent/BR112014014531B1/pt not_active IP Right Cessation
- 2012-12-10 CA CA2859133A patent/CA2859133C/en active Active
- 2012-12-10 DK DK12798738.6T patent/DK2791140T3/en active
- 2012-12-10 WO PCT/EP2012/074977 patent/WO2013087578A1/en not_active Ceased
- 2012-12-10 JP JP2014546445A patent/JP6050829B2/ja not_active Expired - Fee Related
- 2012-12-10 MY MYPI2014701550A patent/MY178660A/en unknown
- 2012-12-10 SI SI201230702A patent/SI2791140T1/sl unknown
- 2012-12-10 CU CU2016000039A patent/CU24426B1/es unknown
- 2012-12-10 EP EP12798738.6A patent/EP2791140B1/en active Active
- 2012-12-10 ME MEP-2016-181A patent/ME02517B/me unknown
- 2012-12-10 UA UAA201407930A patent/UA116768C2/uk unknown
- 2012-12-10 AU AU2012350750A patent/AU2012350750B2/en not_active Ceased
- 2012-12-10 IN IN4310CHN2014 patent/IN2014CN04310A/en unknown
- 2012-12-10 RS RS20160733A patent/RS55144B1/sr unknown
- 2012-12-10 US US14/365,424 patent/US20140336173A1/en not_active Abandoned
- 2012-12-10 HR HRP20161130TT patent/HRP20161130T1/hr unknown
- 2012-12-12 AR ARP120104679A patent/AR089207A1/es unknown
- 2012-12-12 JO JOP/2012/0377A patent/JO3295B1/ar active
- 2012-12-14 US US13/715,553 patent/US9206184B2/en active Active
- 2012-12-14 TW TW101147336A patent/TWI567076B/zh not_active IP Right Cessation
-
2014
- 2014-05-14 IL IL232611A patent/IL232611A/en active IP Right Grant
- 2014-06-09 CU CUP2014000065A patent/CU20140065A7/es unknown
- 2014-06-09 CO CO14123802A patent/CO7030961A2/es unknown
- 2014-06-10 DO DO2014000127A patent/DOP2014000127A/es unknown
- 2014-06-11 TN TNP2014000255A patent/TN2014000255A1/en unknown
- 2014-06-12 CL CL2014001547A patent/CL2014001547A1/es unknown
- 2014-06-12 EC ECIEPI20144722A patent/ECSP14004722A/es unknown
- 2014-06-13 PH PH12014501355A patent/PH12014501355A1/en unknown
- 2014-06-13 GT GT201400113A patent/GT201400113A/es unknown
- 2014-06-17 CR CR20140288A patent/CR20140288A/es unknown
- 2014-07-14 ZA ZA2014/05140A patent/ZA201405140B/en unknown
-
2016
- 2016-08-31 CY CY20161100853T patent/CY1118112T1/el unknown
-
2017
- 2017-07-17 AU AU2017206140A patent/AU2017206140A1/en not_active Abandoned
-
2018
- 2018-02-20 US US15/900,725 patent/US20190016724A1/en not_active Abandoned
-
2019
- 2019-06-18 AU AU2019204255A patent/AU2019204255A1/en not_active Abandoned
-
2021
- 2021-11-01 US US17/516,542 patent/US20220153745A1/en not_active Abandoned